Warren Mason

57.8k total citations · 5 hit papers
219 papers, 33.3k citations indexed

About

Warren Mason is a scholar working on Genetics, Pulmonary and Respiratory Medicine and Neurology. According to data from OpenAlex, Warren Mason has authored 219 papers receiving a total of 33.3k indexed citations (citations by other indexed papers that have themselves been cited), including 168 papers in Genetics, 95 papers in Pulmonary and Respiratory Medicine and 49 papers in Neurology. Recurrent topics in Warren Mason's work include Glioma Diagnosis and Treatment (168 papers), Brain Metastases and Treatment (74 papers) and Radiomics and Machine Learning in Medical Imaging (35 papers). Warren Mason is often cited by papers focused on Glioma Diagnosis and Treatment (168 papers), Brain Metastases and Treatment (74 papers) and Radiomics and Machine Learning in Medical Imaging (35 papers). Warren Mason collaborates with scholars based in Canada, United States and Switzerland. Warren Mason's co-authors include Roger Stupp, Michael Weller, J. Gregory Cairncross, R.O. Mirimanoff, Thierry Gorlia, Robert C. Janzer, Martin J. van den Bent, Alba A. Brandes, Denis Lacombe and Elizabeth A. Eisenhauer and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Brain.

In The Last Decade

Warren Mason

208 papers receiving 32.7k citations

Hit Papers

Radiotherapy plus Concomitant and Adjuvant Temozolomide f... 2005 2026 2012 2019 2005 2005 2014 2007 2014 5.0k 10.0k 15.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
    2005 16.0k citations Roger Stupp, Warren Mason et al. profile →
  2. MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
    2005 5.2k citations Thierry Gorlia, Michael Weller et al. profile →
  3. Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
    2014 1.8k citations Olivier Chinot, Wolfgang Wick et al. profile →
  4. Paraneoplastic anti– N ‐methyl‐ D ‐aspartate receptor encephalitis associated with ovarian teratoma
    2007 1.7k citations Warren Mason et al. profile →
  5. Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies
    2014 404 citations Warren Mason et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Warren Mason Canada 49 20.5k 10.6k 7.6k 6.8k 6.0k 219 33.3k
Jill S. Barnholtz‐Sloan United States 69 19.6k 1.0× 11.6k 1.1× 9.3k 1.2× 7.6k 1.1× 5.7k 0.9× 435 41.2k
Alba A. Brandes Italy 62 23.6k 1.1× 10.1k 1.0× 9.7k 1.3× 7.5k 1.1× 3.5k 0.6× 359 34.1k
Quinn T. Ostrom United States 48 17.2k 0.8× 9.3k 0.9× 6.4k 0.8× 6.0k 0.9× 5.3k 0.9× 154 31.1k
Michael D. Prados United States 90 18.8k 0.9× 7.9k 0.7× 7.4k 1.0× 4.6k 0.7× 5.2k 0.9× 418 27.6k
David A. Reardon United States 89 20.8k 1.0× 10.4k 1.0× 7.3k 1.0× 7.2k 1.1× 4.0k 0.7× 560 34.0k
Thierry Gorlia Belgium 46 20.6k 1.0× 10.3k 1.0× 8.1k 1.1× 7.3k 1.1× 2.6k 0.4× 158 31.2k
Carol Kruchko United States 47 16.4k 0.8× 8.3k 0.8× 5.9k 0.8× 5.3k 0.8× 5.6k 0.9× 139 29.3k
Henry S. Friedman United States 95 21.5k 1.0× 15.0k 1.4× 7.9k 1.0× 7.5k 1.1× 5.9k 1.0× 567 38.4k
Patrick Y. Wen United States 102 23.9k 1.2× 12.3k 1.2× 11.6k 1.5× 8.0k 1.2× 5.3k 0.9× 781 43.2k
J. Gregory Cairncross Canada 60 24.9k 1.2× 12.5k 1.2× 9.4k 1.2× 8.4k 1.2× 3.6k 0.6× 169 36.1k

Countries citing papers authored by Warren Mason

Since Specialization
Citations

This map shows the geographic impact of Warren Mason's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Warren Mason with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Warren Mason more than expected).

Fields of papers citing papers by Warren Mason

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Warren Mason. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Warren Mason. The network helps show where Warren Mason may publish in the future.

Co-authorship network of co-authors of Warren Mason

This figure shows the co-authorship network connecting the top 25 collaborators of Warren Mason. A scholar is included among the top collaborators of Warren Mason based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Warren Mason. Warren Mason is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rhun, Émilie Le, Sara Erridge, David A. Reardon, et al.. (2025). Proton Pump Inhibitor Use and Survival in Patients With Newly Diagnosed Glioblastoma. JAMA Network Open. 8(11). e2545578–e2545578.
2.
Bent, Martin J. van den, Ingo K. Mellinghoff, Mehdi Touat, et al.. (2024). 10311- ACT-19 A GLOBAL, RANDOMIZED, DOUBLE-BLINDED, PHASE 3 STUDY OF VORASIDENIB VERSUS PLACEBO IN PATIENTS WITH ADULT-TYPE DIFFUSE GLIOMA WITH AN IDH1/2 MUTATION (INDIGO): UPDATED EFFICACY RESULTS. Neuro-Oncology Advances. 6(Supplement_4). iv9–iv9. 2 indexed citations
3.
Katzberg, Hans, Vera Bril, Warren Mason, et al.. (2024). Myasthenia Gravis in Patients Treated With Immune Checkpoint Inhibitors. JTO Clinical and Research Reports. 6(5). 100772–100772.
4.
Groot, John Frederick De, Timothy F. Cloughesy, Donald A. Berry, et al.. (2024). Evaluation of VAL-083 in GBM AGILE, a phase 3 registration platform trial for newly diagnosed and recurrent glioblastoma.. Journal of Clinical Oncology. 42(16_suppl). 2005–2005.
5.
Mellinghoff, Ingo K., Martin J. van den Bent, Deborah T. Blumenthal, et al.. (2023). KS02.6.A INDIGO: A GLOBAL, RANDOMIZED, DOUBLE-BLINDED, PHASE III STUDY OF VORASIDENIB VERSUS PLACEBO IN PATIENTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1/2 MUTATION. Neuro-Oncology. 25(Supplement_2). ii4–ii5.
6.
O’Kane, Grainne M., Warren Mason, Pavlina Spiliopoulou, et al.. (2023). Circulating Oncometabolite 2-hydroxyglutarate as a Potential Biomarker for Isocitrate Dehydrogenase (IDH1/2) Mutant Cholangiocarcinoma. Molecular Cancer Therapeutics. 23(3). 394–399. 6 indexed citations
7.
Shultz, David, et al.. (2022). Bevacizumab for Cerebral Radionecrosis: A Single-Center Experience. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. 50(4). 573–578. 7 indexed citations
8.
Mason, Warren, et al.. (2022). Clinical features of glioma patients who develop pneumocystis pneumonia with temozolomide chemoradiotherapy. Journal of Neuro-Oncology. 159(3). 665–674. 2 indexed citations
9.
Mason, Warren, et al.. (2021). Neuro-Oncology Clinicians’ Attitudes and Perspectives on Medical Assistance in Dying. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. 48(6). 1–7. 3 indexed citations
10.
Tyndel, Felix, et al.. (2021). Periodic Alternating Gaze Deviation Due to Paraneoplastic Cerebellar Degeneration. Movement Disorders Clinical Practice. 8(5). 791–793. 2 indexed citations
11.
Muñoz, David G., et al.. (2020). Glioblastoma Spinal Cord Metastasis With Short-Term Clinical Improvement After Radiation. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. 47(6). 869–871.
12.
Brandes, Alba A., J. Gregory Cairncross, Keyue Ding, et al.. (2020). Temozolomide and seizure outcomes in a randomized clinical trial of elderly glioblastoma patients. Journal of Neuro-Oncology. 149(1). 65–71. 17 indexed citations
13.
Macdonald, David R., et al.. (2020). Prolonged response to vismodegib in a patient with systemic medulloblastoma metastases. BMJ Case Reports. 13(10). e236406–e236406. 1 indexed citations
14.
Laperrière, Normand, et al.. (2020). Outcomes of presumed malignant glioma treated without pathological confirmation: a retrospective, single-center analysis. Neuro-Oncology Practice. 7(4). 446–452. 4 indexed citations
15.
Sim, Hao‐Wen, Romina Nejad, Wenjiang Zhang, et al.. (2019). Tissue 2-Hydroxyglutarate as a Biomarker for Isocitrate Dehydrogenase Mutations in Gliomas. Clinical Cancer Research. 25(11). 3366–3373. 21 indexed citations
16.
Sandmann, Thomas, Richard Bourgon, Josep Garcia, et al.. (2015). Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial. Journal of Clinical Oncology. 33(25). 2735–2744. 208 indexed citations
17.
Klein, Martin, Roger Henriksson, Andrew Bottomley, et al.. (2013). HEALTH-RELATED QUALITY OF LIFE (HRQOL) ANALYSES IN THE AVAGLIO STUDY, A RANDOMIZED, PLACEBO-CONTROLLED PHASE III TRIAL OF BEVACIZUMAB, TEMOZOLOMIDE AND RADIOTHERAPY IN NEWLY DIAGNOSED GLIOBLASTOMA. Neuro-Oncology. 15. 232–232. 4 indexed citations
18.
Perry, James, Karl Bélanger, Warren Mason, et al.. (2010). Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study. Journal of Clinical Oncology. 28(12). 2051–2057. 264 indexed citations
19.
Wick, Wolfgang, Vinay K. Puduvalli, Marc C. Chamberlain, et al.. (2010). Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma. Journal of Clinical Oncology. 28(7). 1168–1174. 359 indexed citations
20.
Kovács, Kálmán, et al.. (2009). USE OF TEMOZOLOMIDE IN AGGRESSIVE PITUITARY TUMORS. Neurosurgery. 64(4). E773–E774. 68 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jill S. Barnholtz‐Sloan Breakdown of academic impact, for papers by Alba A. Brandes Breakdown of academic impact, for papers by Quinn T. Ostrom Breakdown of academic impact, for papers by Michael D. Prados Breakdown of academic impact, for papers by David A. Reardon Breakdown of academic impact, for papers by Thierry Gorlia Breakdown of academic impact, for papers by Carol Kruchko Breakdown of academic impact, for papers by Henry S. Friedman Breakdown of academic impact, for papers by Patrick Y. Wen Breakdown of academic impact, for papers by J. Gregory Cairncross
Rankless by CCL
2026